News
Neurophyxia B.V. was incorporated on April 20th, 2008 and is privately held.
| April 2008: |
Closing of First financing round. Acquisition of the 2-IB patent family, originally filed by University Medical Center Utrecht. |
| July 2008: | Pre-IND meeting with the US FDA |
| September 2008: | Start of formal preclinical development of 2-IB (manufacturing and safety studies) |
| October 2008: | First financing milestones achieved. |
| January 2009: | Granting of "Innovatiekrediet" loan by the Dutch Ministry of Economic Affairs. |
| June 2009: |
Second financing milestone achieved. Granting of Orphan Drug designation by the US FDA. |
| October 2009: | Successful completion of safety studies required for Phase I clinical studies |
| December 2009: | Start of Phase I clinical study |
| January 2010: | Granting of Orphan Drug designation in the European Union by the European Commission |
| February 2010: | Initiation of protocol advice procedure with the European Medicines Agency (EMA) in London (for Phase II clinical study) |